Accredited CME/NCPD/CPE Podcasts

Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise!

Click here to claim your CME credit: i3health.com/course-information/podcast-ddlps

Diagnosis and Management of Dedifferentiated Liposarcoma: A Multidisciplinary Task Force Podcast

Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.

In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!

Click here to claim CME/NCPD credit: https://bit.ly/49NCaQu

What’s New With HER2: Charting New Paths in NSCLC Care Module 1 Podcast: HER2 in NSCLC: Actionable Insights and Testing Recommendations

Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.

In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!

Click here to claim CME/NCPD credit: https://bit.ly/405xEJO

What’s New With HER2: Charting New Paths in NSCLC Care Module 2 Podcast

Join Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, in Module 1 of this podcast series as she explores the challenges of diagnosing systemic mastocytosis (SM), a rare and often under recognized mast cell disease. 

In this episode, Dr. Castells discusses the wide range of SM symptoms—including anaphylaxis, cutaneous, gastrointestinal, neuropsychiatric, and musculoskeletal manifestations—and offers essential guidance on recognizing the signs, confirming the diagnosis, and improving patient outcomes through early intervention. 

Listen now to enhance your clinical knowledge and be sure to claim your credit after the episode!

Click on the link to claim your credit now: https://bit.ly/3Y3ivHM

Click here to continue listening to Module 2 of this podcast series: https://bit.ly/43VoFNP

Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 1

Tune in to Module 2 of our podcast series as Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, explores strategies for developing personalized management plans for patients with systemic mastocytosis (SM). This episode covers the latest advancements in treatment, including tyrosine kinase inhibitors (TKIs), supportive care interventions, and practical approaches to tailoring therapies based on disease subtype and symptom burden. Listen now to stay up to date on best practices for improving patient outcomes and quality of life—and don’t forget to claim your credit after the episode!

Click here to claim credit for this activity: https://bit.ly/43VoFNP

Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 2

Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually.

Click here to listen to module 2 of this podcast series: bit.ly/44yO9RB

Click here to claim your CME/NCPD credit: bit.ly/4iYmYD2

Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes - Module 1

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments.

Click here to go back and listen to module 1 of this podcast series: https://bit.ly/4iYmYD2

Click here to claim your CME/NCPD credit: https://bit.ly/44yO9RB

Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes  Module 2

Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape.

Click here to claim your credit for this podcast:

Challenges and Innovations in Biliary Tract Cancer: A Multidisciplinary Task Force Perspective

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: https://bit.ly/45u106o

Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: https://bit.ly/3HtOziO

Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit:

Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.

🎧 Listen now and click the link to claim your CE credit!

Claim your credit here: bit.ly/4pGrLO5

🔗 Learn more and access continuing education activities: i3health.com

📲 Stay connected with i3 Health:

Twitter/X: https://bit.ly/3ITDaJV
Facebook: https://bit.ly/46wmwJo
YouTube: https://bit.ly/46PXLXx

🎧 Subscribe to the Oncology Data Advisor Podcast on your favorite streaming platform so you never miss the latest expert discussions!

Optimizing CLL Care: Pharmacist-Led Strategies for Treatment Selection and Toxicity Management

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Accredited CME/NCPD/CPE Podcasts

Oncology Data Advisor®